Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more
Shanghai Yizhong Pharmaceutical Co Ltd (688091) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.014x
Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) has a cash flow conversion efficiency ratio of 0.014x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥21.03 Million) by net assets (CN¥1.46 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Yizhong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Yizhong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sichuan Chuanhuan Technology Co Ltd
SHE:300547
|
-0.006x |
|
Premier Investments Ltd
AU:PMV
|
0.041x |
|
Legend Holdings Corporation
PINK:LGNRF
|
-0.003x |
|
5I5j Holding Group Co Ltd
SHE:000560
|
0.055x |
|
Empire State Realty Trust Inc
NYSE:ESRT
|
0.059x |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
-0.138x |
|
Hyundai Department
KO:069960
|
0.049x |
|
QI7
F:QI7
|
N/A |
Annual Cash Flow Conversion Efficiency for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.41 Billion | CN¥39.44 Million | 0.028x | -52.50% |
| 2023-12-31 | CN¥1.46 Billion | CN¥86.55 Million | 0.059x | -29.64% |
| 2022-12-31 | CN¥1.32 Billion | CN¥110.78 Million | 0.084x | +302.36% |
| 2021-12-31 | CN¥1.18 Billion | CN¥-48.78 Million | -0.041x | +50.00% |
| 2020-12-31 | CN¥243.51 Million | CN¥-20.21 Million | -0.083x | +7.88% |
| 2019-12-31 | CN¥265.35 Million | CN¥-23.91 Million | -0.090x | -78.92% |
| 2018-12-31 | CN¥212.18 Million | CN¥-10.68 Million | -0.050x | +13.58% |
| 2017-12-31 | CN¥197.57 Million | CN¥-11.51 Million | -0.058x | -- |